Clinical pharmacokinetics of melatonin: a systematic review - PubMed (original) (raw)

Review

Clinical pharmacokinetics of melatonin: a systematic review

Nathja Groth Harpsøe et al. Eur J Clin Pharmacol. 2015 Aug.

Abstract

Purpose: The aim of the review was to provide an overview of studies investigating the pharmacokinetics of exogenous melatonin in humans and if possible, to provide recommendations for clinical use.

Methods: The review was conducted in accordance to PRISMA guidelines. A systematic literature search was performed in PubMed and Embase databases. The pharmacokinetic variables included maximal plasma/serum concentration (Cmax), time to maximal plasma/serum concentration (Tmax), elimination half-life (T1/2), area-under-the-curve plasma/serum concentrations (AUC), clearance (Cl), volume of distribution (VD), and bioavailability.

Results: The literature search identified 392 records. Twenty-two studies were included in the review. Melatonin dosages varied between 0.3 and 100 mg and were administered either orally or intravenously. Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral). Tmax ranged between 15 (2 mg) and 210 min (10 mg). T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral). Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral). Bioavailability of oral melatonin ranged from 9 to 33%. Pharmacokinetics was affected by age, caffeine, smoking, oral contraceptives, feeding status, and fluvoxamine. Critically ill patients displayed accelerated absorption and compromised elimination.

Conclusions: Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin. T1/2 was 45 min in both administration routes. Cmax, AUC, Cl, and VD varied extensively between studies. Bioavailability of oral melatonin was approximately 15%.

PubMed Disclaimer

Similar articles

• Pharmacokinetics of oral and intravenous melatonin in healthy volunteers.
  Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, Gögenur I. Andersen LP, et al. BMC Pharmacol Toxicol. 2016 Feb 19;17:8. doi: 10.1186/s40360-016-0052-2. BMC Pharmacol Toxicol. 2016. PMID: 26893170 Free PMC article. Clinical Trial.
• Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
  Chen C, Bujanover S, Kareht S, Rapoport AM. Chen C, et al. Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24. Headache. 2015. PMID: 25546369 Clinical Trial.
• Pharmacokinetics of Alternative Administration Routes of Melatonin: A Systematic Review.
  Zetner D, Andersen LP, Rosenberg J. Zetner D, et al. Drug Res (Stuttg). 2016 Apr;66(4):169-73. doi: 10.1055/s-0035-1565083. Epub 2015 Oct 29. Drug Res (Stuttg). 2016. PMID: 26514093 Review.
• Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery.
  Harpsøe NG, Andersen LP, Mielke LV, Jønsson B, Jenstrup MT, Gögenur I, Rosenberg J. Harpsøe NG, et al. Clin Drug Investig. 2016 Dec;36(12):1045-1050. doi: 10.1007/s40261-016-0452-5. Clin Drug Investig. 2016. PMID: 27566320
• Clinical pharmacokinetics of mizolastine.
  Lebrun-Vignes B, Diquet B, Chosidow O. Lebrun-Vignes B, et al. Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.

Cited by

• Melatonin for Neuropathic Pain: Protocol for a Double-blind, Randomized Controlled Trial.
  Gilron I, Tu D, Holden RR, Moulin DE, Duggan S, Milev R. Gilron I, et al. JMIR Res Protoc. 2022 Sep 28;11(9):e40025. doi: 10.2196/40025. JMIR Res Protoc. 2022. PMID: 36170003 Free PMC article.
• The Functional Medicine Approach to COVID-19: Virus-Specific Nutraceutical and Botanical Agents.
  Evans JM, Luby R, Lukaczer D, Rountree R, Stone PM, Guilliams TG, Yanuck S, Messier H, Ramsdell K, Hanaway PJ. Evans JM, et al. Integr Med (Encinitas). 2020 May 9;19(Suppl 1):34-42. Integr Med (Encinitas). 2020. PMID: 33041706 Free PMC article. Review.
• Melatonin as a Chronobiotic with Sleep-promoting Properties.
  Cruz-Sanabria F, Carmassi C, Bruno S, Bazzani A, Carli M, Scarselli M, Faraguna U. Cruz-Sanabria F, et al. Curr Neuropharmacol. 2023;21(4):951-987. doi: 10.2174/1570159X20666220217152617. Curr Neuropharmacol. 2023. PMID: 35176989 Free PMC article. Review.
• Efficacy of a premedication with melatonin during cataract surgery under peribulbar block: a prospective randomized double-blinded study.
  Khouadja H, Mighri F, Knani L, Mahjoub A, Nour H, Ben Jazia K. Khouadja H, et al. Tunis Med. 2022 Octobre;100(10):713-718. Tunis Med. 2022. PMID: 36571756 Free PMC article. Clinical Trial.
• Effect of melatonin in patients with low anterior resection syndrome (MELLARS): a study protocol for a randomised, placebo-controlled, crossover trial.
  Zahid JA, Madsen MT, Bulut O, Christensen P, Gögenur I. Zahid JA, et al. BMJ Open. 2023 Sep 11;13(9):e067763. doi: 10.1136/bmjopen-2022-067763. BMJ Open. 2023. PMID: 37696629 Free PMC article.

References

1. 1. J Gerontol A Biol Sci Med Sci. 1998 Jul;53(4):B293-8 - PubMed
2. 1. J Clin Pharmacol. 2008 Feb;48(2):240-5 - PubMed
3. 1. Br J Clin Pharmacol. 1985 Apr;19(4):517-21 - PubMed
4. 1. Int J Surg. 2010;8(5):336-41 - PubMed
5. 1. N Engl J Med. 1997 Apr 3;336(14):1028-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database